[1]刘力,罗霜,程书文,等.ZFTA融合室管膜瘤的诊治研究进展[J].中国临床神经外科杂志,2024,29(05):299-303.[doi:10.13798/j.issn.1009-153X.2024.05.013]
　LIU Li,LUO Shuang,CHENG Shu-wen,et al.Diagnosis, treatment and prognosis of ZFTA fusion ependymomas[J].,2024,29(05):299-303.[doi:10.13798/j.issn.1009-153X.2024.05.013]
点击复制

ZFTA融合室管膜瘤的诊治研究进展()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年05期
页码:
299-303
栏目:
综述
出版日期:
2024-05-30

文章信息/Info

Title:
Diagnosis, treatment and prognosis of ZFTA fusion ependymomas
文章编号:
1009-153X（2024）05-0299-05
作者:
刘力; 罗霜; 程书文; 龚敏; 周广平; 王翔
611470成都，四川大学华西医院神经外科（刘力、王翔）；611130，成都市第五人民医院神经外科（刘力、罗霜、程书文、龚敏、周广平）
Author(s):
LIU Li1; 2;  LUO Shuang2;  CHENG Shu-wen2;  GONG Min2;  ZHOU Guang-ping2;  WANG Xiang1
1. Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 611047, China; 2. Department of Neurosurgery, Chengdu Fifth People's Hospital, Chengdu 611130, China
关键词:
室管膜瘤; ZFTA融合型; 诊断; 治疗; 预后
Keywords:
Ependymoma;  ZFTA fusion type;  Diagnosis;  Treatment;  prognosis
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2024.05.013
文献标志码:
A
摘要:
室管膜瘤包括多种类型，可发生在幕上腔室、颅后窝或脊髓。世界卫生组织（WHO）根据特定的解剖部位、组织学、基因表型的特征，对室管膜肿瘤分类系统进行了多次更新，并应用新的分类系统来预测评估病人的治疗结果。2021年，WHO组织更新分类，因为ZFTA融合阳性室管膜瘤的基因融合不仅涉及RELA，还包含如MAML2/3、NCOA1/2、MN1或CTNNA2等基因融合，所以室管膜瘤ZFTA融合阳性型成为了最新的室管膜瘤类型。本文通过回顾幕上室管膜瘤分类的变化、临床特点及治疗进展，概述ZFTA融合室管膜瘤的临床表现与治疗策略选择方面的研究进展，希望能对ZFTA融合室管膜瘤这一新定义的幕上肿瘤的认识和诊疗提供参考价值。
Abstract:
Ependymomas encompass a diverse array of subtypes, occurring in the supratentorial space, posterior fossa, or spinal cord. The World Health Organization (WHO) has periodically revised the classification system for ependymal tumors to account for specific anatomical features, histology, and genetic phenotypes. These updates have been instrumental in predicting and evaluating treatment outcomes for patients. In 2021, WHO further updated the classification to include ZFTA fusion-positive ependymoma as a distinct subtype due to its involvement of gene fusions such as RELA, MAML2/3, NCOA1/2, MN1 or CTNNA2. This paper reviewed the evolving classification criteria and treatment advancements for supratentorial ependymoma while summarizing research progress on clinical manifestations and treatment strategies for ZFTA fused ependymoma in order to provide valuable insights into understanding, diagnosing and treating this newly defined supratentorial tumor.

参考文献/References:

[1]LOUIS DN, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary [J]. Acta Neuropathol, 2016, 131(6): 803-820.
[2]MACK SC, WITT H, PIRO RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy [J]. Nature, 2014, 506(7489): 445-450.
[3]TAMAI S, NAKANO Y, KINOSHITA M, et al. Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features [J]. Brain Tumor Pathol, 2021, 38(1): 64-70.
[4]YANG D, HOLSTEN T, BORNIGEN D, et al. Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology [J]. Brain Pathol, 2021, 31(1): 33-44.
[5]MANGALORE S, ARYAN S, PRASAD C, et al. Imaging characteristics of supratentorial ependymomas: study on a large single institutional cohort with histopathological correlation [J]. Asian J Neurosurg, 2015, 10(4): 276-281.
[6]YU BL, WANG SJ, ZHANG M et al. CT and MR diagnosis of supratentorial parenchymal ependymoma [J]. Chin J Radiol, 1997, 45(11): 42-46. 鱼博浪，王世捷，张　明，等. 幕上脑实质室管膜瘤CT和MR诊断[J]. 中华放射学杂志，1997，45（11）：42-46.
[7]RENI M, BRANDES AA. Current management and prognostic factors for adult ependymoma [J]. Expert Rev Anticancer Ther, 2002, 2 (5): 537-545.
[8]IM SH, PAEK SH, CHOI YL, et al. Clinicopathological study of seven cases of symptomatic supratentorial subependymoma [J]. J Neurooncol, 2003, 61(1): 57-67.
[9]ZHOU H, VALLIRES M, BAI HX, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas [J]. Neuro Oncol, 19(6): 862-870.
[10]SHAO H, CHEN N, SU X, et al. Magnetic resonance imaging features of zinc finger translocation associated-RELA fusion ependymoma compared to its wild-type counterpart [J]. World Neurosurg, 2023, 175: e1283-e1291.
[11]PAGAS M, PAJTLER KW, PUGET S, et al. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging [J]. Brain Pathol, 2019, 29(3): 325-335.
[12]ZHAO F, WU T, WANG LM, et al. Survival and prognostic factors of adult intracranial ependymoma: a single-institutional analysis of 236 patients [J]. Am J Surg Pathol, 2021, 45(7): 979-987.
[13]PAJTLER KW, WITT H, SILL M, et al. Molecular classification of ependymal tumors across all cns compartments, histopathological grades, and age groups [J]. Cancer Cell, 2015, 27(5): 728-743.
[14]HOU J, CHEN N, ZHENG LM, et al. Clinicopathological analysis of 13 cases of RELA gene fusion ependyma [J]. J Diag pathol, 2021, 28(7): 552-556, 561. 侯　静，陈　铌，郑林茂，等. 13例RELA基因融合型室管膜瘤临床病理分析[J]. 诊断病理学杂志，2021，28（7）：552-556，561.
[15]WANG L, LIU L, LI H, et al. RELA fusion in supratentorial extra-ventricular ependymomas: a morphologic, immunohistochemical, and molecular study of 43 cases [J]. Am J Surg Pathol, 2019, 43(12): 1674-1681.
[16]WANG Q, CHENG J, ZHANG S, et al. Supratentorial pediatric cortical ependymomas: a comprehensive retrospective study [J]. Neurosurg Rev, 2021, 44(3): 1543-1551.
[17]MERCHANT TE, BENDEL AE, SABIN ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma [J]. J Clin Oncol, 2019, 37(12): 974-983.
[18]METELLUS P, GUYOTAT J, CHINOT O, et al. Adult intracranial WHO grade Ⅱ ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients [J]. Neuro Oncol, 2010, 12 (9): 976-984.
[19]RUD R, REIFENBERGER G, FRAPPAZ D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors [J]. Neuro Oncol, 2018, 20(4): 445-456.
[20]WANG Q, CHENG J, LI J, et al. The survival and prognostic factors of supratentorial cortical ependymomas: a retrospective cohort study and literature-based analysis [J]. Front Oncol, 2020, 10: 1585.
[21]VENKATRAMANI R, JI L, LASKY J, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" Ⅲ prospective clinical trial [J]. J Neurooncol, 2013, 113(2): 285-291.
[22]WU XX, YANG YY, ZHOU YD, et al. Clinical analysis of supratentorial ependymoma in children [J]. Chin J Nerv Ment Dis, 2021, 47 (7): 418-421. 吴宣萱，杨贇滢，周渝冬，等. 儿童幕上脑实质内室管膜瘤临床分析[J]. 中国神经精神疾病杂志，2021，47（7）：418-421.
[23]GARVIN JH JR, SELCH MT, HOLMES E, et al. Phase Ⅱ study of pre-irradiation chemotherapy for childhood intracranial ependymoma: Children's Cancer Group protocol 9942: a report from the Children's Oncology Group [J]. Pediatr Blood Cancer, 2012, 59(7): 1183-1189.
[24]NG CH, OBRECHT D, WELLS O, et al. A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma [J]. Neurooncol Adv, 2023, 5(1): vdad057.
[25]LUNDAR T, DUE-TENNESSEN BJ, EGGE A, et al. Neurosurgical treatment of brain tumors in the first 6 months of life: long-term follow-up of a single consecutive institutional series of 30 patients [J]. Childs Nerv Syst, 2015, 31(12): 2283-2290.
[26]KARAKOULA K, SUAREZ-MERINO B, WARD S, et al. Realtime quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13 [J]. Genes Chromosomes Cancer, 2008, 47(11): 1005-1022.
[27]DEWIRE M, FOULADI M, TURNER DC, et al. An open-label, two-stage, phase Ⅱ study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) [J]. J Neurooncol, 2015, 123(1): 85-91.
[28]TABORI U, WONG V, MA J, et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma [J]. Br J Cancer, 2008, 99(7): 1129-1135.
[29]LIANG ML, HSIEH TH, LIU YR, et al. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas [J]. Oncotarget, 2017, 9(2): 2527-2542.
[30]PAJTLER KW, TIPPELT S, SIEGLER N, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors [J]. J Neurooncol, 2016, 128(3): 463-471.
[31]MACK SC, PAJTLER KW, CHAVEZ L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling [J]. Nature, 2018, 553(7686): 101-105.

相似文献/References:

[1]胡栓贵　乔广宇　黄进能　朱寿鸿　洪翰明　李亚平　黄珩沙.显微手术治疗脊髓髓内室管膜瘤14例[J].中国临床神经外科杂志,2015,(08):485.[doi:10.13798/j.issn.1009-153X.2015.08.014]
[2]吴胜梅　张桂萍　肖　姗　秦秀萍　王桂花　王　萍.1例高颈段髓内室管膜瘤术后并发呼吸机依赖1年的护理体会[J].中国临床神经外科杂志,2017,(12):856.[doi:10.13798/j.issn.1009-153X.2017.12.020]
[3]康　剑　李维平　陈保东　陈　垒　刘悦琤.左侧侧脑室室管膜瘤术前合并颅内感染1例[J].中国临床神经外科杂志,2020,(05):336.[doi:10.13798/j.issn.1009-153X.2020.05.029]
[4]邬迎喜　王晋浩　薛亚飞　张韫泽　赵天智.第四脑室内室管膜瘤种植转移至延髓1例[J].中国临床神经外科杂志,2022,27(03):237.[doi:10.13798/j.issn.1009-153X.2022.03.031]
[5]唐志坚,吴雅奇,张俊,等.脊髓圆锥区室管膜瘤的显微手术疗效分析[J].中国临床神经外科杂志,2022,27(12):967.[doi:10.13798/j.issn.1009-153X.2022.12.003]
　TANG Zhi-jian,WU Ya-qi,ZHANG Jun,et al.Microsurgery for patients with conical intramedullary ependymoma[J].,2022,27(05):967.[doi:10.13798/j.issn.1009-153X.2022.12.003]
[6]李天栋,杨瑞鑫,邹宇辉,等.脊髓室管膜瘤的显微手术治疗体会[J].中国临床神经外科杂志,2023,28(06):395.[doi:10.13798/j.issn.1009-153X.2023.06.012]

备注/Memo

备注/Memo:
（2023-12-20收稿，2024-03-24修回）
基金项目：四川省重点研发项目（2023YFS0271）
通信作者：王　翔，Email：wangxiangtim@163.com
更新日期/Last Update: 2024-05-30